Brief: ANI Pharmaceuticals Q3 Adjusted EPS USD 2.04 Vs. IBES Estimate USD 1.75
07/11/2025 11:50
Nov 07 (Reuters) - ANI Pharmaceuticals Q3 EPS USD 1.13. Q3 net income USD 26.3 million Q3 revenue USD 227.8 million vs. IBES estimate USD 211 million Q3 adjusted EBITDA USD 59.6 million outlook FY revenue USD 854-873 million outlook FY adjusted EBITDA USD 221-228 million outlook FY adjusted EPS USD 7.37-7.64
Recent news on ANI Pharmaceuticals
See all newsBrief: Ani Pharmaceuticals Announces The Launch Of Duloxetine Delayed-Release Capsules
Brief: Ani Pharmaceuticals Announces The FDA Approval Of Everolimus Tablets For Oral Suspension
Brief: Ani Pharmaceuticals Appoints Henry Gosebruch To Board Of Directors
U.S. RESEARCH ROUNDUP-Compass Minerals, Duke Energy, Tesla
ANI Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary